--- title: "Kiora Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285712795.md" datetime: "2026-05-08T11:08:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285712795.md) - [en](https://longbridge.com/en/news/285712795.md) - [zh-HK](https://longbridge.com/zh-HK/news/285712795.md) --- # Kiora Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.58. EBIT: As of FY2026 Q1, the actual value is USD -2.65 M. Kiora Pharmaceuticals, Inc. operates as a single reportable segment focused on ophthalmic pharmaceutical products, with performance evaluated at the consolidated company level; however, research and development (R&D) expenses are tracked by product candidate . #### Operational Metrics for Three Months Ended March 31: - **General and Administrative Expenses:** Increased to $1,612,267 in 2026 from $1,489,398 in 2025, driven by higher director and personnel costs, and professional services . - **Total Research and Development Expenses:** Decreased to $2,123,725 in 2026 from $2,531,887 in 2025, primarily due to a $1.0 million decrease in preclinical and CMC-related expenses, partially offset by a $0.4 million increase in clinical trial costs and decreased credits from Australian and Austrian government R&D programs . - **KIO-101 R&D Expenses:** Were $0 in 2026, down from $3,014 in 2025 . - **KIO-104 R&D Expenses:** Were $287,009 in 2026, compared to - $149,326 in 2025 (net of research tax credit offset) . - **KIO-301 R&D Expenses:** Were $1,560,107 in 2026, down from $2,101,850 in 2025 . - **Unallocated R&D Expenses:** Decreased to $276,609 in 2026 from $576,349 in 2025, primarily including personnel costs, research consulting, and scientific advisory expenses . - **Collaboration Credits:** Decreased to - $1,233,224 in 2026 from - $1,966,123 in 2025, reflecting decreased R&D expenses for the KIO-301 program, which are fully reimbursed by Théa Open Innovation (TOI) . - **Change in Fair Value of Contingent Consideration:** Decreased to $7,427 in 2026 from $275,192 in 2025, primarily due to an increased discount rate and changes to the development plan . - **Other Income, Net:** Decreased to $92,212 in 2026 from $260,380 in 2025, mainly due to lower interest income from reduced interest rates and a lower balance of short-term marketable securities, alongside unrealized losses from foreign currency activity . - **Income Tax Provision:** Was $0 in 2026, compared to an expense of $123,006 in 2025, with the 2025 figure reflecting a change in estimate for the 2024 tax year due to new legislation . - **Net Loss:** Increased to - $2,417,983 in 2026 from - $2,192,980 in 2025 . #### Cash Flow for Three Months Ended March 31: - **Net Cash Used in Operating Activities:** Increased to - $3,161,332 in 2026 from - $2,704,199 in 2025, primarily due to a higher net loss, decreases in non-cash change in fair value of contingent consideration, and unfavorable changes in operating assets and liabilities . - **Net Cash Provided by Investing Activities:** Increased to $5,400,982 in 2026 from $2,672,782 in 2025, mainly due to a decrease in marketable securities purchases, partially offset by decreased proceeds from maturities of marketable securities . - **Net Cash Used in Financing Activities:** Was - $842 in 2026, compared to $0 in 2025 . #### Future Outlook and Strategy: Kiora Pharmaceuticals, Inc. anticipates having sufficient cash to fund planned operations into late 2028, based on $11.0 million in cash and cash equivalents, $2.9 million in short-term investments at March 31, 2026, and an additional $5 million received in April 2026 from a private placement transaction . The company expects to incur significant expenses and increasing operating losses, necessitating additional financing through various means such as equity offerings, debt, collaborations, and grants . While KIO-301 expenses are fully reimbursed by its partner TOI, development work on KIO-101 is currently paused and available for partnership . ### Related Stocks - [KPRX.US](https://longbridge.com/en/quote/KPRX.US.md) ## Related News & Research - [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Sangoma Announces Third Quarter Fiscal 2026 Results | SANG Stock News](https://longbridge.com/en/news/286317217.md)